# Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic

> **NCT06109831** · PHASE2 · COMPLETED · sponsor: **Beijing Suncadia Pharmaceuticals Co., Ltd** · enrollment: 335 (actual)

## Conditions studied

- Hyperlipidemic

## Interventions

- **DRUG:** SHR-1918
- **DRUG:** SHR-1918 placebo

## Key facts

- **NCT ID:** NCT06109831
- **Lead sponsor:** Beijing Suncadia Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-24
- **Primary completion:** 2025-07-04
- **Final completion:** 2025-07-04
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06109831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06109831, "Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06109831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*